YUM70
Based on 4 publication(s) in Google Scholar
YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC50 of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in a pancreatic cancer xenograft model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.01%
- No. CAS: 423145-35-1
- Fòrmula: C21H19ClN2O4
- Peso molecular:398.84
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Cuproptosis Compound Library
HY-L133
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) YUM70
More
Actividad biológica
|
Grp78 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| BXPC-3 | IC50 |
9.6 μM
Compound: 21; YUM70
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell proliferation incubated for 4 hrs by MTS assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell proliferation incubated for 4 hrs by MTS assay
|
[PMID: 37690265] |
| MCF7 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| MIA PaCa-2 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 37690265] |
| NCI-H1299 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37690265] |
| OVCAR-3 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| OVCAR-8 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| PANC-1 | IC50 |
4.5 μM
Compound: 21; YUM70
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 37690265] |
| SH-SY5Y | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human SH-SY5Y cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SH-SY5Y cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| SK-OV-3 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
YUM70 shows selective cytotoxicity for MIA PaCa-2, PANC-1, BxPC-3 cells (IC50=2.8, 4.5, and 9.6 μM, respectively) over normal pancreatic tissue-derived HPNE cells (IC50>30 μM)[1].
YUM70 (5 μM; 24 h) induces endoplasmic reticulum (ER) stress-mediated apoptosis of MIA PaCa-2cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MIA PaCa-2, PANC-1 cells
-
Concentration:0.1, 1, 2.5, 5, 10 μM
-
Incubation Time:2, 4, 8, 24, 48 hours
-
Result:Increased the protein levels of FAM129A, DDIT3, CHAC-1, DDIT4, UPP1, and GRP78 in a dose- and time-dependent manner.
YUM70 (15 mg/kg; i.v.) exhibits t1/2 (1.40 h), CL (724.04 mL/h/kg), and Vss (1162.73 mL/kg) in mice[1].
YUM70 (30 mg/kg; p.o.) exhibits bioavailability (6.71%), t1/2 (2.74 h), and CL (9230.15 mL/h/kg) in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week old female NCr nude mice were injected with MIA PaCa-2 cells[1]
-
Dosage:30 mg/kg
-
Administration:I.p. 5 days a week for 7 weeks
-
Result:Observed a significant tumor growth delay with no significant change in body weight during the course of treatment.
Chemical Information
-
No. CAS 423145-35-1
-
Appearance Solid
-
Peso molecular 398.84
-
Fòrmula C21H19ClN2O4
-
Color White to off-white
-
SMILES
CCCC(NC(C1=CC=C(OCO2)C2=C1)C3=CC(Cl)=C4C=CC=NC4=C3O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Mol Biomed
Death-associated protein kinase 2 (DAPK2) propagates endoplasmic reticulum stress in macrophages to worsen sepsis through HSPA5-IRE1α axis. [Abstract]2026 Jun 23;7(1):94. PMID: 42334722 -
EMBO Mol Med
NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5. [Abstract]2023 Nov 8;15(11):e17761. PMID: 37807968 -
Mol Cancer Ther
Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. [Abstract]2026 Feb 11. PMID: 41670299 -
Solvente y solubilidad
DMSO : 100 mg/mL (250.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.27 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5073 mL | 12.5364 mL | 25.0727 mL | 62.6818 mL |
| 5 mM | 0.5015 mL | 2.5073 mL | 5.0145 mL | 12.5364 mL | |
| 10 mM | 0.2507 mL | 1.2536 mL | 2.5073 mL | 6.2682 mL | |
| 15 mM | 0.1672 mL | 0.8358 mL | 1.6715 mL | 4.1788 mL | |
| 20 mM | 0.1254 mL | 0.6268 mL | 1.2536 mL | 3.1341 mL | |
| 25 mM | 0.1003 mL | 0.5015 mL | 1.0029 mL | 2.5073 mL | |
| 30 mM | 0.0836 mL | 0.4179 mL | 0.8358 mL | 2.0894 mL | |
| 40 mM | 0.0627 mL | 0.3134 mL | 0.6268 mL | 1.5670 mL | |
| 50 mM | 0.0501 mL | 0.2507 mL | 0.5015 mL | 1.2536 mL | |
| 60 mM | 0.0418 mL | 0.2089 mL | 0.4179 mL | 1.0447 mL | |
| 80 mM | 0.0313 mL | 0.1567 mL | 0.3134 mL | 0.7835 mL | |
| 100 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6268 mL |
YUM70 Related Classifications
HY-138364 Related Classifications
Powered by Bioz